Oct. 13 at 12:17 PM
Cantor reiterated Top Pick
$VERA at an Overweight rating and a
$100 PT
$VRTX $OHSKY $NVS
Cantor Fitzgerald said:
With P3 data in hand, a BLA filing this Q, and a potential approval/launch in mid-'26, we are highlighting 10 reasons we are bullish on VERA, a "Top Pick," and its candidate atacicept (APRIL/BAFF inh; Breakthrough Designation) for IgA nephropathy (IgAN).
With detailed P3 ORIGIN 36-wk data that will support the BLA filing coming in the near-term (likely at ASN Nov 6-9), we continue to see VERA shares as undervalued (
$1.X.9B market cap with
$557M in cash as of 3Q25) as the blockbuster potential for atacicept is overlooked in IgAN alone.
